Darvadstrocel is a novel treatment option for this complex and devastating disease that has been demonstrated to help patients achieve and sustain clinical remission for up to 104 weeks.
In a paper presented at the Crohn’s & Colitis Congress 2022, investigators from Cedars-Sinai Medical Center in Los Angeles reported on their research into social media posts by Crohn disease patients with fistulizing disease, which shed new light on patients’ experiences and concerns.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
In an oral abstract presented at the ACG meeting, investigators concluded that e-cigarette use—both current and former—is independently associated with a risk of peptic ulcer disease.
In an oral abstract presented at the ACG meeting, investigators concluded that e-cigarette use—both current and former—is independently associated with a risk of peptic ulcer disease.
An ongoing randomized, controlled phase III study will evaluate the clinical efficacy, safety, and pharmacodynamic effect of tinengotinib for refractory/relapsed cholangiocarcinoma.
An ongoing randomized, controlled phase III study will evaluate the clinical efficacy, safety, and pharmacodynamic effect of tinengotinib for refractory/relapsed cholangiocarcinoma.
Intercept Pharmaceuticals will voluntarily withdraw its obeticholic acid product, Ocaliva, from the US market for the treatment of primary biliary cholangitis.
Intercept Pharmaceuticals will voluntarily withdraw its obeticholic acid product, Ocaliva, from the US market for the treatment of primary biliary cholangitis.